

Contents

Preface and Acknowledgements	xi
Abbreviations	xiii
List of Contributors	xv
Part 1: The Choice of Appropriate Tumor Systems to be Used as Models	
1. Commentary on Parts 1 and 2 <i>Robert F. Kallman</i>	3
2. Differences Between Mouse and Human Tumors that Affect Their Responses to Radiotherapy <i>Klaus-Rüdiger Trott</i>	6
3. Satisfactory and Unsatisfactory Tumor Models: Factors Influencing the Selection of a Tumor Model for Experimental Evaluation <i>Dietmar W. Siemann</i>	12
4. Choice of Appropriate Tumor Systems: Acute Leukemia <i>Anton Hagenbeek</i>	16
5. How to Determine Tumor Immunogenicity <i>M. J. Embleton</i>	19
6. Factors Influencing Tumor Cell Immunogenicity <i>Edith M. Lord</i>	23
Part 2: The Maintenance of Experimental Tumors and Factors that Affect Their Response to Therapy	
7. Maintenance of Tumor Systems and Appropriate Treatment Techniques for Experimental Tumors <i>Sara Rockwell</i>	29

- | | |
|---|----|
| 8. Effect of Animal Husbandry on Misonidazole Toxicity and Pharmacokinetics | 37 |
| <i>John E. Moulder</i> | |
| 9. Circulation Physiology of Tumors | 39 |
| <i>H. S. Reinhold and A. E. van den Berg-Blok</i> | |
| 10. Spontaneous Variations of Blood Supply and Tissue Temperature in Peripheral Subcutaneous Tumors During Anesthesia | 43 |
| <i>W. Mueller-Klieser and Peter Vaupel</i> | |
| 11. Some Artefacts Involved in the Radiation Response of Mouse Tumors Arising from Anesthesia and Physical Restraint | 47 |
| <i>Gillian M. Tozer</i> | |

Part 3: The Tumor Host: Genetics and Ethical Principles

- | | |
|---|----|
| 12. Commentary on Part 3 | 53 |
| <i>Robert F. Kallman</i> | |
| 13. On the Use of Animals in Research | 54 |
| <i>Nicholas J. McNally</i> | |
| 14. Practices for Controlling Genetic Quality of Mice | 57 |
| <i>Donald W. Bailey and O. C. A. Scott</i> | |
| 15. Genetic Monitoring of Laboratory Animals | 59 |
| <i>Artemio A. Ovejera and Maciej Czerwinski</i> | |

Part 4: Measurement of Effects on Tumors by Clonogenicity Assays

- | | |
|---|-----|
| 16. Commentary on Part 4 | 65 |
| <i>Robert F. Kallman</i> | |
| 17. Excision Assays | 67 |
| <i>Richard P. Hill</i> | |
| 18. Characterization of Cell Suspensions from Solid Tumors | 76 |
| <i>Maria G. Pallavicini</i> | |
| 19. How Should a Disaggregation Method be Evaluated? | 82 |
| <i>Peter R. Twentyman</i> | |
| 20. Timing: An Important Variable in Colony-Formation Assays | 84 |
| <i>Kenneth T. Wheeler, Jr., and C. Anne Wallen</i> | |
| 21. Measurement of Tumor Cell Surviving Fraction and Absolute Numbers of Clonogens per Tumor in Excision Assay: | 90 |
| <i>Trevor C. Stephens</i> | |
| 22. Clonogenic Tumor Cell Release Assay and Its Application to Tumor Biology | 95 |
| <i>Norio Suzuki</i> | |
| 23. Morphometry of Irradiated Tumors | 97 |
| <i>Ingo Brammer and Horst Jung</i> | |
| 24. The Growth of Viable Tumor Cells Injected into Sterilized Tumors | 101 |
| <i>J. Kummermehr and J. Buschmann</i> | |

25. Direct Analysis of Tumor Control Data <i>Howard D. Thames, Jr.</i>	103
26. The Colony Assay in Dose Fractionation Experiments <i>Hans-Peter Beck-Bornholdt and Hubert Vogler</i>	106
Part 5: Measurement of Effects on Tumors by Growth/Regrowth Assays	
27. Commentary on Part 5 <i>Robert F. Kallman</i>	111
28. Principles and Practices of the Tumor Growth Delay Assay <i>Adrian C. Begg</i>	114
29. Some Practical Questions in the Tumor Regrowth Assay <i>Muneyasu Urano and Julia Kahn</i>	122
30. Relationship between Tumor Growth Delay and Modification of Local-Control Probability of Various Treatments Given as an Adjuvant to Irradiation <i>J. Overgaard, M. Matsui, J. Chr. Lindegaard, C. Grau, C. Zachariae, I. M. Johansen, H. von der Maase, and O. S. Nielsen</i>	128
Part 6: Measurement of Effects by Tumor Control Assays	
31. Commentary on Part 6 <i>Robert F. Kallman</i>	135
32. Radiation Dose-Response Assays of Tumor Control <i>Herman D. Suit, Robert Sedlacek, and Howard D. Thames, Jr.</i>	138
33. Tumor Control Rate as Related to Cell Survival <i>H. S. Reinhold and A. P. van den Berg</i>	149
34. Significance of the Slope of the Curve of Tumor Control versus Radiation Dose <i>James V. Moore</i>	152
35. Design of Radiation Dose-Response Assays for Tumor Control <i>Herman D. Suit, Tzong Yueh Hwang, Chung-cheng Hsieh, and Howard D. Thames, Jr.</i>	154
Part 7: The Tumor Bed—Blood Circulation, Nontumor Cells, Tumor Bed Effect	
36. Commentary on Part 7 <i>Robert F. Kallman</i>	167
37. Detection and Characterization of Clonogenic Host Cells in Experimental Tumors <i>Trevor C. Stephens and J. H. Peacock</i>	169
38. Tumor Bed Effect: Dependency on Tumor Type and Influence on Tumor Therapy <i>Luka Milas</i>	174

39. To What Extent May Nonmalignant Cells In or Near Tumors Influence Tumor Responses Resulting from Therapy? 179
A. F. Hermens
40. Consequences of the Tumor Bed Effect for Regrowth Delay Studies 189
J. Martin Brown

Part 8: The Use of Human Tumor Xenografts, or Alternative In Vitro Methods

41. Commentary on Part 8 197
Robert F. Kallman
42. The Suitability and Use of Human Tumor Xenografts 199
Janet A. Houghton and Peter J. Houghton
43. How Well Do Xenografts Maintain the Therapeutic Response Characteristics of the Source Tumor in the Donor Patient? 205
G. Gordon Steel
44. Radioresponsiveness of Human Tumor Xenografts: Growth Delay and Vascular Damage 209
Einar K. Rofstad
45. Blood Flow and Oxygen Consumption of Primary and Xenotransplanted Human Mammary Carcinomas 214
F. Kallinowski, H. Runkel, and Peter Vaupel
46. The Use of Human Tumor Xenografts in Large-Scale Drug Screening 218
Artemio A. Ovejera
47. Human Melanoma Cell Lines: A Useful Model for Intratumor Heterogeneity 221
Claudia Greco and G. Zupi
48. Spheroids as Models of Tumor Microregions: Importance of Cell-Cell and Cell-Microenvironmental Interactions 223
Robert M. Sutherland

Part 9: Complications Associated with Therapeutic Modalities and/or Their Combinations

49. Commentary on Part 9 231
Robert F. Kallman
50. Rodent Models in Experimental Chemotherapy 233
Thomas H. Corbett and Frederick A. Valeriote
51. The Evaluation of Combinations of Cytotoxic Drugs and Radiation: Isobolograms and Therapeutic Synergism 248
Trevor C. Stephens and G. Gordon Steel
52. The Emergence of Drug Resistance in Experimental Tumors: Selection and Characterization of Resistant Cells 253
Trevor C. Stephens
53. Peculiarities of Intratumor Pharmacokinetics of Antineoplastic Agents 258
Peter Vaupel

54. Methods to Study “Minimal Residual Disease” Illustrated by Studies in a Rat Model for Human Acute Myelocytic Leukemia (BNML) <i>Anton Hagenbeek</i>	261
55. Cell-Cycle Effects and Scheduling <i>Lyle A. Dethlefsen</i>	264
56. The Use of Acridine Orange Assays to Determine Growth Fraction <i>C. Anne Wallen</i>	265
57. Time-of-Exposure Factors in Experimental Chemotherapy <i>Peter R. Twentyman</i>	267
Part 10: Comparisons of Different Assays and Conclusions	
58. Commentary on Part 10 <i>Robert F. Kallman</i>	271
59. Comparison of Tumor Assay Methods <i>John E. Moulder and Sara Rockwell</i>	272
60. Relative Biological Effectiveness of Fast Neutrons Determined by Three Endpoints <i>Koichi Ando, Sachiko Koike, and Nobuo Fukuda</i>	279
References	283
Index	306
About the Editor	310